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Background: We evaluated ultrasonography variables associated with the improvement of nocturia
after administration of alpha adrenoceptor antagonist (alpha blocker) monotherapy.
Methods: From February to October 2014, 679 men with lower urinary tract symptoms (LUTS) un-
derwent ultrasonography including prostate volume, transitional zone volume, prostatic urethral
length, the ratio between prostatic urethral length and prostate volume (RPUL), intravesical prostatic
protrusion (IPP), and prostatic urethral angle (PUA). Among them, 108 men who had pre-treatment
nocturia without nocturnal polyuria (nocturnal polyuria index < 33%) and were treated with alpha
blocker monotherapy over 3 months were enrolled. Patients were divided into the improved (< 2
times of nocturia) and non-improved group (more than 2 times) after administration of alpha blockers.
Along with ultrasonography, international prostate symptom score (IPSS) and uroﬂowmetry was
assessed.
Results: After alpha blocker treatment, 25.0% of patients (27/108) showed improvement of nocturia.
These patients were signiﬁcantly younger (59.6 vs 68.0 years, P ¼ < 0.001) with lower PUA (31.8 vs. 39.4,
P ¼ 0.009) compared with the non-improved group. In ROC analysis, the area under the curve using the
PUA was 0.653 (95% CI ¼ 0.532e0.774, P ¼ 0.018). Using 33.5 as a cut-off level, the sensitivity and
speciﬁcity for predicting the improvement of nocturia after medication reached 67.9% and 55.6%,
respectively. Patients with lower PUA (PUA < 33.5) had more improvement of nocturia (36.6 vs. 17.9%,
P ¼ 0.030), lower IPSS score (14.2 vs. 18.3, P ¼ 0.005), and better quality of life index (3.1 vs 3.8,
P ¼ 0.021).
Conclusions: In the patients with lower PUA (particularly lower than 33.5), nocturia was improved by
administration of alpha blocker monotherapy.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nocturia, which is usually included as a lower urinary tract
symptom (LUTS), is a common cause of an adult sleep disorder (e.g.,
obstructive sleep apnea, enuresis). A recent meta-analysis suggests
that the prevalence rate of nocturia was 11e43.9% in youngerungpook National University
uth Korea.
ciﬁc Prostate Society, Published bpersons (i.e., 20e40 years) and 68.9e93% in older persons (i.e.,
> 70 years).1 Nocturia is not a simple LUTS; it is a multifactorial
condition with many contributing etiological factors. It has four
major underlying causes: global polyuria, nocturnal polyuria,
bladder storage disorders, or mixed etiology.2 Nocturia is often
associated with men with benign prostatic hyperplasia (BPH).3 The
effect of an alpha adrenoceptor antagonist (i.e., an alpha blocker) on
nocturia was demonstrated in patients with BPH. It may reduce
residual urine and thus increase the room for nocturnal urine
storage.4 However, the improvement in nocturia is clinically mar-
ginal, poorly sustained, and depends on the patients.5y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Kim et al / Prostatic urethral angle and nocturia 31We hypothesized that individual differences in the effect of an
alpha blocker can be attributed to structural differences of the
prostate. To provide an integral description of individual differ-
ences in the prostate, we evaluated ultrasonography variables
associated with the improvement of nocturia after the adminis-
tration of alpha blocker monotherapy.
2. Materials and methods
2.1. Patient enrollment
This multicenter cross-sectional study was conducted using the
same protocol in ﬁve tertiary care hospitals in the Daegu area
(Dongguk University Kyeongju Hospital, Keimyung University
Dongsan Medical Center, Kyungpook National University Hospital,
Kyungpook National University Medical Center, Yeungnam Uni-
versity Medical Center, Daegu, Korea), after the approval of the local
Institutional Review Board (approval number, 13-0496-O82). Six
hundred and seventy-nine men were examined from February
2014 to October 2014. Of these,108menwere included in this study
who had pretreatment nocturia (deﬁned as  2 awakenings at
night to void) and were treated with alpha blockers monotherapy
(i.e., tamsulocin, doxazocin, alfuzocin, terazocin, naftopidil, or
silodocin) for > 3 months (average, 11.5 months; range,
3e102 months). However, patients with nocturnal polyuria (i.e.,
nocturnal polyuria index > 33%) were excluded from this study.
Other exclusion criteria were as follows: presence of an indwelling
urinary catheter, previous prostate surgery or pelvic radiation,
urethral stricture, inﬂammation of urinary tract, prostate or bladder
cancer, and neurogenic bladder disease. Patients were divided by
the improved group (i.e., < 2 episodes of nocturia) and the non-
improved group (i.e.,  2 episodes of nocturia) after the adminis-
tration of alpha blockers.
2.2. Parameter measurements
Detailed previous medical history, particularly BPH medication
(e.g., use of alpha blockers, 5-a reductase inhibitors (5ARIS),
phosphodiesterase inhibitors, antimuscarinic agents, and desmo-
pressin) at the time of evaluation and previous admission or BPH-
related surgical history was obtained from all enrolled patients.
We reviewed the degree of LUTS at pretreatment by using clinical
records of the international prostate symptom score (IPSS) and
voiding diary. At post-treatment, routine subjective assessment of
the degree of LUTS was performed using the IPSS and voiding diary,Fig. 1. Ultrasonographic measurement of prostatic urethral angle and Intravesical prostati
Intravesical prostatic protrusion measured on the ultrasound image.and objective assessment was performed using uroﬂowmetry and
transrectal ultrasonography examination. Along with total IPSS,
scores divided according to obstructive symptoms (Questionnaires
1, 3, 5, and 6), irritative symptoms (Questionnaires 2, 4, and 7), and
quality of life (Questionnaire 8) were also utilized as a separate
clinical indicator. Bothersome voiding symptoms, particularly the
presence of nocturia were also evaluated. After treatment with
alpha blocker monotherapy, uroﬂowmetry was performed in the
usual manner. The amount of post-voiding residual urine was
measured using ultrasonography. Patients also underwent trans-
rectal ultrasonography (TRUS) for the evaluation of LUTS at post-
treatment. During TRUS, the prostate volume, transitional zone
volume, prostatic urethral length, the ratio between prostatic ure-
thral length and prostate volume (RPUL), intravesical prostatic
protrusion (IPP), and prostatic urethral angle (PUA) were deter-
mined during a single session. The prostate and transitional zone
volume were measured by calculating the maximal height, width,
and length on ultrasonography (i.e., 0.52  transverse
diameter  anteroposterior diameter  cephalocaudal diameter).
The prostatic urethral length was measured by the continuous
tracing of the route of the urethra, which runs within the apex to
the base of the prostate via the midsagittal image of ultrasonog-
raphy. The measured prostatic urethral length was then utilized to
describe the individual morphologic variation of the prostate [i.e.,
RPUL (mm/mL)]. The IPP was measured by TRUS when the bladder
volume was 100e200 mL. The degree of IPP was graded by
measuring from the tip of the protruding gland perpendicular to
the bladder circumference at the prostate base in the midsagittal
plane. The PUA is the angle formed by two rays of the proximal and
distal prostatic urethra on the midsagittal plane image, and was
taken with the posterior wall of the prostate positioned as ﬂat as
possible tominimize the inﬂuence of pressure from the rectal probe
(Fig. 1).
2.3. Data and statistical analysis
The correlation between the improvement in nocturia after
alpha blocker monotherapy and clinical parameters such as age,
prostate-speciﬁc antigen (PSA), post-treatment IPSS, post-
treatment uroﬂowmetry, and post-treatment ultrasonography
variables were analyzed. Patients were divided into two groups,
according to improvement in nocturia after the administration of
alpha blockers. Differences in parameters between groups were
assessed using the ManneWhitney U test. A receiver operating
characteristic (ROC) curve was drawn and the sensitivity andc protrusion. (A) The prostatic urethral angle measured on the ultrasound image. (B)
Table 1
Clinical parameters based on the improvement in nocturia after the use of alpha blockers.
Nonimproved group Improved group P
(n ¼ 81) (n ¼ 27)
Age (y) 68.0 ± 9.4 59.6 ± 9.9 < 0.001
Prostate-speciﬁc antigen (ng/mL) 1.8 ± 2.1 2.2 ± 2.7 0.416
Transrectal ultrasonography
Total prostate volume (mL) 29.8 ± 15.4 33.1 ± 18.1 0.368
Transition zone volume (mL) 13.4 ± 12.2 14.0 ± 13.4 0.831
Urethral length (cm) 4.0 ± 0.6 4.0 ± 0.7 0.764
RPUL (mm/mL) 1.5 ± 0.5 1.4 ± 0.4 0.102
PUA () 39.4 ± 12.6 31.8 ± 12.3 0.009
IPP (cm) 0.17 ± 0.4 0.21 ± 0.5 0.665
Post-treatment international prostate symptom score
Total score 17.9 ± 7.9 13.4 ± 5.2 0.008
Voiding symptom score 10.5 ± 5.7 9.0 ± 4.0 0.133
Storage symptom score 7.4 ± 3.3 4.5 ± 2.2 < 0.001
Quality of life index 3.7 ± 1.4 3.0 ± 1.4 0.030
Post-treatment uroﬂowmetry
Qmax. (mL/s) 11.9 ± 6.5 16.9 ± 6.6 0.002
Voiding volume (mL) 205.8 ± 126.8 254.5 ± 185.1 0.129
Postvoid residual volume (mL) 45.4 ± 54.7 30.3 ± 42.6 0.195
IPP, intravesical prostatic protrusion; PUA, prostatic urethral angle; Qmax, maximum ﬂow rate; RPUL, the ratio between prostatic urethral length and prostate volume.
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The best cut-off point was chosen according to the ROC curve. The
area under the curve was also calculated. The results were
expressed with a 95% conﬁdence interval (CI). Univariate and
multivariate analyses performed to determine the improvement in
nocturia were assessed using logistic regression analysis. Statistical
analysis was performed using SPSS 21.0 for Windows software
(SPSS Inc., Chicago, IL, USA). The signiﬁcance level for all analyses
was set at P < 0.05.
3. Results
After alpha blocker monotherapy treatment, 25.0% (27/108) of
patients showed improvement in nocturia. In comparison with the
nonimproved group, these patients were signiﬁcantly younger
(59.6 years vs. 68.0 years, P 0.001) with a lower IPSS (13.4 vs. 17.9,
P ¼ 0.008), lower storage symptom score (4.5 vs. 7.4, P  0.001),
better quality of life index (3.0 vs. 3.7, P ¼ 0.030), and higher
maximum ﬂow rate (Qmax; 16.9 mL/s vs. 11.9 mL/s; P ¼ 0.002) at
post-treatment. On TRUS, the nocturia group had a lower PUA
(31.8 vs. 39.4, P ¼ 0.009; Table 1).
In univariate logistic analysis, age and the PUAwere signiﬁcantly
associated with presence of nocturia (P  0.001 and P  0.010,
respectively). In multivariate analysis, age and the PUA were also
signiﬁcantly associated with nocturia (P ¼ 0.001 and P ¼ 0.021,
respectively; Table 2).
In ROC analysis, the area under the curve using the PUA was
0.653 [95% CI, 0.532e0.774; P ¼ 0.018; Fig. 2]. Using 33.5 as the
cut-off level, the sensitivity and speciﬁcity for predicting theTable 2
Logistic regression analysis used to determine the factors that predict improvement in n
Univariate analysis
Odds ratio (95% CI)
Age (y) 1.095 (1.041e1.095)
Transrectal ultrasonography
Total prostate volume (mL) 0.989 (0.964e1.014)
Transition zone volume (mL) 0.996 (0.963e1.031)
Urethral length (cm) 1.116 (0.567e2.197)
RPUL (mm/mL) 2.348 (0.839e6.576)
PUA () 1.055 (1.013e1.099)
IPP (cm) 0.784 (0.263e2.334)
CI, conﬁdence interval; IPP, intravesical prostatic protrusion; PUA, prostatic urethral angimprovement of nocturia aftermedication reached 67.9% and 55.6%,
respectively.
Patients with lower PUA (i.e., < 33.5) hadmore improvement in
nocturia [36.6% vs. 17.9%, P ¼ 0.030], compared to patients with a
higher PUA (i.e., 33.5). On the post-treatment IPSS, patients with
a lower PUA had a lower total IPSS score (14.2 vs. 18.3, P ¼ 0.005),
lower voiding symptom score (8.6 vs. 11.0, P¼ 0.025), lower storage
symptom score (5.6 vs. 7.3, P ¼ 0.006), and better quality of life
index (3.1 vs. 3.8, P ¼ 0.021) (Table 3).
4. Discussion
Nocturia (i.e., nocturnal waking to void) occurs in up to 58.90%
of people older than 50 years.6,7 Its prevalence increases with
age.8,9 This condition can signiﬁcantly impair a patient's perception
of his or her well-being.10,11 The International Continence Society
deﬁnition of nocturia is a complaint of having to awaken once or
more at night to void.2 However, the traditional deﬁnition of noc-
turia is a complaint of having to awaken twice or more at night to
void. In a cross-sectional, community-based epidemiologic survey
conducted in Korea, the mean number of nocturia episodes was
2.05 times for menwith BPH and 1.04 times for menwithout BPH.12
Many studies on nocturia only consider patients with two or more
voids per night, based on the observation that a nocturnal fre-
quency of one void per night does not appear to be harmful or
bothersome.13,14 Therefore, in this study, nocturia was deﬁned as
awakening twice during sleep to void.
The etiology of nocturia recently included four major underlying
causes: global polyuria, nocturnal polyuria, bladder storageocturia.
Multivariate analysis
P Odds ratio (95% CI) P
< 0.001 1.094 (1.035e1.155) 0.001
0.372 0.999 (0.882e1.132) 0.989
0.829 1.019 (0.902e1.152) 0.762
0.750 0.889 (0.218e3.632) 0.870
0.287 3.955 (0.419e37.343) 0.230
0.010 1.059 (1.008e1.111) 0.021
0.662 0.674 (0.159e2.860) 0.593
le; RPUL, the ratio between prostatic urethral length and prostate volume.
Fig. 2. The graph shows the receiver operating characteristic curves for prostatic
urethral angle (AUC ¼ 0.653, P ¼ 0.018). AUC, area under the curve.
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ment (BPE) often have nocturia and nocturnal polyuria.3 Benign
prostatic enlargement leading to bladder outlet obstruction (BOO)
clearly results in the obstructive type of voiding symptoms which
comprises poor ﬂow, hesitancy, prolonged stream, and terminal
dribbling. In addition, storage symptoms are common in males in
these age groups. However, as demonstrated in a cohort of 324 trial
participants, urological problems were the only cause of nocturia in
just 16% of patients.15 Patients with nocturia who do not have
polyuria or nocturnal polyuria based on the aforementioned
criteria will most likely have a bladder storage disorder that re-
duces their nighttime voided volume or a sleep disorder.16
One of the most pertinent aspects of the relationship between
nocturia and BPE is whether successful treatment of BPE resolves
nocturia. Margel et al17 report that nocturia appears to improve
after transurethral resection of the prostate. Medical treatmentTable 3
Clinical parameters based on a prostatic urethral angle of 33.5 .
PUA < 33.5 PUA  33.5 P
(n ¼ 41) (n ¼ 67)
Improvement in nocturia (%) 36.6 17.9 0.030
Age (y) 63.8 ± 11.0 67.2 ± 9.6 0.094
Prostate-speciﬁc antigen (ng/mL) 1.6 ± 2.0 2.2 ± 2.3 0.167
Transrectal ultrasonography
Total prostate volume (mL) 29.8 ± 15.4 31.2 ± 16.6 0.667
Transition zone volume (mL) 12.7 ± 12.5 14.0 ± 12.5 0.599
Urethral length (cm) 3.8 ± 0.5 4.1 ± 0.7 0.004
IPP (cm) 0.1 ± 0.3 0.2 ± 0.4 0.082
Post-treatment international prostate symptom score
Total score 14.2 ± 7.6 18.3 ± 7.1 0.005
Voiding symptom score 8.6 ± 5.4 11.0 ± 5.2 0.025
Storage symptom score 5.6 ± 3.2 7.3 ± 3.1 0.006
Quality of life index 3.1 ± 1.5 3.8 ± 1.3 0.021
Post-treatment uroﬂowmetry
Qmax. (mL/s) 14.1 ± 6.1 12.6 ± 7.2 0.296
Voiding volume (mL) 223.1 ± 146.4 214.9 ± 143.8 0.776
Postvoid residual volume (mL) 31.4 ± 45.6 47.9 ± 55.2 0.111
PUA, prostatic urethral angle; Qmax, maximum ﬂow rate.with alpha blockers could similarly be indicated for male patients
with nocturia when BPE is suspected. In a study17 with terazosin,
27% of patients reported that nocturia was reduced by more than
half, and 14% reported that it was reduced by 25e49% on the
frequency-volume chart. On the IPSS, 31% of patients reported that
the treatment reduced their nocturia by more than half and 27%
reported a reduction of 25e49%.18 However, in another trial,19,20 the
clinical signiﬁcance of alpha blockers was doubted because the
difference in nocturia episodes was too small between patients
receiving treatment with alpha blockers and a placebo. A study
with alfuzosin also reported a numerical improvement of 1.1
voids per night versus 0.8 with placebo (P ¼ 0.04).19 In the Vet-
erans Administration Cooperative Study, nocturia decreased from a
baseline mean of 2.5 episodes to 1.8 episodes, 2.1 episodes, 2.0
episodes, and 2.1 episodes in the terazosin group, ﬁnasteride,
combination group, and placebo group, respectively.20
With regard to the medical treatment of BPH, 5ARI (e.g.,
dutasteride and ﬁnasteride) effectively reduced the prostate vol-
ume.21 However, alpha blockers provide rapid relief of LUTS, pre-
sumably by relaxing the smooth muscle tone in the prostate and
bladder neck.22 In addition, the effect of alpha blockers on the
structure of the prostate remains unknown. In our study, we did not
have pretreatment TRUS data.
However, we believed that alpha blocker monotherapy would
not change the structure of the prostate. We also hypothesized that
structural features of the prostate could predict improvement in
nocturia after alpha blocker monotherapy. Therefore, we investi-
gated ultrasonography variables to provide an integral description
of the individual structural differences of the prostate. As a result of
this study, the PUA was the only structural variable that could
predict improvement of nocturia after treatment by alpha blockers.
The PUA is a well-known structural feature of the prostate. In a
study by Ku et al,23 higher PSA levels, larger prostate volume,
higher maximal urethral closure pressure, higher detrusor pressure
at maximum ﬂow rate, and higher BOO index were reported with a
larger PUA. Using multivariate analysis, Bang et al24 reported that
PUA has an independent association with the IPSS. Hou et al25 re-
ported a change in symptoms after treatment with alpha blocker. In
this study, the PUA had an independent association with the IPSS
(P ¼ 0.001) and Qmax (P ¼ 0.004). After tamsulosin therapy, the
PUA was associated with post-treatment IPSS change (P ¼ 0.032)
and post-treatment Qmax change (P ¼ 0.001).
However, the relationship between the PUA and nocturia has
not been reported. In the current study, patients with improved
nocturia were signiﬁcantly younger and had a lower PUA.
Age is a well-known factor in progression of nocturia.3 The
incidence and prevalence of nocturia showed a clear increase with
age. H€akkinen et al26 estimated the incidence and natural course of
nocturia in an unselected Finnish male population. Every year, 10%
more males older than 50 years start to void during the night. The
incidence of mild nocturia increases, particularly in men aged
50e60 years. Older men with mild symptoms are more stable, but
the incidence of severe nocturia increases signiﬁcantly after the age
of 75 years. Thus, in younger patients, a higher improvement rate of
nocturia after alpha blocker monotherapy is very reasonable.
However, the relationship between the PUA and nocturia is
meaningful. The value of the PUA is also conﬁrmed by univariate
analysis and multivariate analysis. In this report, we used a PUA of
33.5 as the cut-off level. We then determined that patients with a
lower PUA had lower incidences of nocturia, lower total IPSS score,
and better quality of life index. The cut-off level was slightly
different according to the paper23,27 (34e35); however, a lower
PUA has generally been associated with improvement in symptoms
and quality of life.23,27 In this report, a lower PUA was also associ-
ated with an improvement in nocturia. In our opinion, a lower PUA
Prostate Int 4 (2016) 30e3534indicates that the urethra is straighter. Relaxing smooth muscle
tone by alpha blockers provides more rapid relief of LUTS in a
straight urethra. Therefore, it seems that nocturia also improved
more in patients with a straight urethra.
In this study, we attempted to ﬁnd other ultrasonography var-
iables for predicting improvement of nocturia after alpha blocker
monotherapy. Benign prostatic enlargement, which is a well-
recognized feature of male aging, is commonly associated with
LUTS. However, opinions are divided on whether prostatic
enlargement has a causal relationship with storage symptoms such
as nocturia.28 In this paper, the total prostate volume and transition
zone volume did not show a statistical difference between the
improved group and the nonimproved group (P ¼ 0.368 and
P ¼ 0.831, respectively). The RPUL is the relationship between the
whole prostate and the prostate urethra. There are multitudinous
patterns that consequently produce distinctive structural variation.
The structural variation of the prostatic urethrawithin the prostate,
as reﬂected by the ratio between prostate volume and prostatic
urethral length, showed a correlationwith the degree of LUTS.29We
believe that the change in the urethrawithin the prostate due to the
enlargement of the glanddinstead of the prostate volume
itselfdmay cause the development of nocturia. However no sta-
tistical difference was observed between the two groups
(P ¼ 0.102).
Intravesical prostatic protrusion is a useful predictor of infra-
vesical obstruction, Qmax, acute urinary retention, and the out-
comes of a trial without a catheter after acute urinary
retention.30e32 In our study, IPP also showed no statistical differ-
ence between the improved group and the nonimproved group
(P ¼ 0.665).
The authors recognize several limitations of this series. First, this
trial was a multicenter prospective study conducted in ﬁve clinics.
We tried to minimize deviation, although there was some technical
difﬁculty. Second, many kinds of alpha blockers were used in this
trial. A few recent studies reporting the effect of a selective alpha-
1D blocker, naftopidil, on nocturia concluded that naftopidil was
better than tamsulosin for treating nocturia.33 However, differences
between alpha blockers were not reﬂected in this study. Third, we
only investigated patients who had nocturia without a decrease in
the number of episodes after alpha blocker monotherapy. Fourth,
most importantly, we did not report the change in TRUS ﬁndings
before and after treatment. Further trials with a proper study
designwill be required to overcome these limitations and to obtain
a solid answer for nocturia and anatomical variations of the
prostate.
In patients who had a lower PUA (particularly lower than 33.5),
nocturia was improved by administration of alpha blocker mono-
therapy. These ﬁndings suggest an individualized approach in the
treatment of nocturia, based on anatomical characteristics illus-
trated by ultrasonography.Conﬂicts of interest
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